Navigation Links
Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
Date:12/13/2011

izartinib in 7-day cycles between chemotherapy, and continuous dosing of quizartinib layered on top of chemotherapy.  Effect of the different treatments was measured by effects on tumor growth delay, tumor burden, tumor regression levels over time.

The results of these preclinical studies demonstrated that both low and high doses of quizartinib can be safely combined with the Ara-C + DNR chemotherapy regimen, and that there was no antagonism between the treatments, regardless of schedule or dose.  Dosing quizartinib in combination with Ara-C, or in combination with Ara-C + DNR, resulted in improved effect on tumor burden, tumor growth delay and tumor regression versus dosing either agent or regimen alone.  Continuous dosing of quizartinib layered on top of chemotherapy produced the best results.  In Study 3, the combination of continuous quizartinib and Ara-C + DNR lead to rapid and complete regression which was sustained for a longer period of time versus any other treatment arm.  For episodic dosing, high dose quizartinib post Ara-C had improved results compared to initiating quizartinib post DNR.  Supported by these findings, a Phase 1 clinical study has recently been initiated to evaluate the combination of quizartinib and standard induction and consolidation chemotherapy in newly diagnosed AML patients.

About Quizartinib

Quizartinib, formerly known as AC220, is being developed in collaboration between Ambit Biosciences and Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor.  Quizartinib is currently under evaluation in a Phase 2 clinical trial as monotherapy treatment for adult and elderly patients with relapsed/refractory AML that have an internal tandem duplication (ITD) mutation in the FLT3 gene.

About Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a form of blood cancer. 
'/>"/>

SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. Ambit Biosciences Announces Transition in Company Leadership
3. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
4. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
5. Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back
6. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
7. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
8. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
9. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... November 24, 2014 2014 Deep ... Industry is a professional and in-depth research report ... Dihydrazide information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Apiscent ... supplier of fine chemical ingredients to the global ... launch of its new website, Apiscent.com. , The ... Apiscent Labs, clean design, easy navigation, rotating images ... Apiscent Labs stand out. , The ...
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), ... scientific testing methodologies relating to cannabis, today announced that ... of credit from an existing stockholder of the Company. ... this commitment from one of our existing stockholders,” stated ... capital will help accelerate our planned expansions into the ...
(Date:11/22/2014)... 22, 2014 Respiratory therapy students ... proper management of life-like respiratory ailments using the ... . Grand Rapids-based, Michigan Instruments Inc. developers of ... of the respiratory simulation units to the pro-gram, ... Valley and Muskegon Community College are collaborating to ...
Breaking Biology Technology:Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3CannLabs Secures $750,000 Line Of Credit 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3
... proxy, FOR the Election of, Two ... May 15 /PRNewswire/ - The Concerned Shareholders of Biovail ... (TSX:BVF) continues to mislead its shareholders by making the ... requisition was simply about governance reform and has already ...
... Nile Therapeutics, Inc. (Nasdaq: NLTX ... therapeutics for heart failure patients, received notification from the ... has released the Company,s CD-NP development program from clinical ... the FDA the finalized protocol for the Company,s planned ...
... Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced ... 15 Proteolix, Inc. today announced that data from ... solid tumors will be presented at the 2009 Annual ... being held May 29 - June 2, 2009 in ...
Cached Biology Technology:The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 2The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 3The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 4The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 5The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 6The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 7Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 2Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 3Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 2Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 3
(Date:11/3/2014)... Research and Markets has announced the ... Markets and Companies" to their offering. ... which have already started to play an important role in ... the old fashioned bone marrow transplants. Role of cells in ... become a part of medical practice. Stem cells ...
(Date:11/3/2014)...  NeuroSigma ® , Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ... neurological and neuropsychiatric disorders, announced today that the ... Notice of Allowance for Mexican Patent Application No. ... and the Regents of the University of California ...
(Date:11/2/2014)... of Physics World , James Dacey explores the ... death" to take their innovations from the lab into ... challenge facing all start-up companies as they move from ... of two main factors: physics-based inventions are usually far ... out to be a lot more complicated than had ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2
... Ariz. (Sept. 13, 2012) -- Shane Snyder, who earlier ... Water Works Association (AWWA), has been invited to present ... 3,500 at the 2012 International Water Association,s (IWA) World ... professor,s presentation will focus not only on his research ...
... Scientists have found the answer to why female killer whales have ... their adult sons. Led by the Universities of Exeter and York ... the research shows that, for a male over 30, the death ... his death within the following year. The reason for the ...
... of bioengineering at Stanford University, has won a Director,s ... award includes a five-year, $2.5 million grant to be ... to affect a broad area of biomedical or behavioral ... to explore the use of synthetic biology platforms and ...
Cached Biology News:UA engineering professor Shane Snyder to speak in Korea on international water quality 2Long menopause allows killer whales to care for adult sons 2Long menopause allows killer whales to care for adult sons 3
SlowFade Antifade Kit with DAPI...
...
... SAGE (serial analysis of ... genome-wide expression analysis. Expression profiles ... enough to detect low-abundance transcripts ... novel genes. The I-SAGE Kit ...
Mycoplasma tested...
Biology Products: